Treatment of dry eye by autologous serum application in Sjögren's syndrome

Br J Ophthalmol. 1999 Apr;83(4):390-5. doi: 10.1136/bjo.83.4.390.

Abstract

Aim: To evaluate the efficacy of autologous serum application for the treatment of dry eye in Sjögren's syndrome.

Methods: The stability of essential components (EGF, vitamin A, and TGF-beta) in preserved serum were examined following preservation at 4 degrees C and -20 degrees C. In a primary clinical trial, 12 patients with Sjögren's syndrome were treated with autologous serum (diluted to 20% with sterile saline) for 4 weeks, and vital staining of the ocular surface was compared before and after treatment. The effects of serum on mucin (MUC-1) expression were observed in cultured conjunctival epithelial cells in vitro.

Results: EGF, vitamin A, and TGF-beta were well preserved for up to 1 month in the refrigerator at 4 degrees C and up to 3 months in the freezer at -20 degrees C. Rose bengal and fluorescein scores improved significantly from the initial scores of 5.3 and 5.6 to 1.7 and 2.5 after 4 weeks, respectively. The additive effect of human serum for cultured conjunctival epithelial cells showed significant MUC-1 upregulation on the cell surface.

Conclusion: Autologous serum application is a safe and efficient way to provide essential components to the ocular surface in the treatment of dry eye associated with Sjögren's syndrome.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blood*
  • Dry Eye Syndromes / therapy*
  • Epidermal Growth Factor / analysis
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mucin-1 / metabolism
  • Ophthalmic Solutions / therapeutic use*
  • Sjogren's Syndrome / complications*
  • Tears / chemistry
  • Transforming Growth Factor beta / analysis
  • Vitamin A / metabolism

Substances

  • Mucin-1
  • Ophthalmic Solutions
  • Transforming Growth Factor beta
  • Vitamin A
  • Epidermal Growth Factor